Literature DB >> 21793434

Efficacy of Newcastle disease virus recombinant expressing avian influenza virus H6 hemagglutinin against Newcastle disease and low pathogenic avian influenza in chickens and turkeys.

Diana Schröer1, Jutta Veits, Günther Keil, Angela Römer-Oberdörfer, Siegfried Weber, Thomas C Mettenleiter.   

Abstract

A recombinant Newcastle disease virus (NDV) expressing H6 hemagglutinin (HA) of a low pathogenic avian influenza virus (LPAIV) was generated by reverse genetics (NDVH6). The H6 open reading frame was inserted as an additional transcription unit between the fusion and hemagglutinin-neuraminidase (HN) gene of lentogenic NDV clone 30. Expression of the foreign gene was demonstrated by northern blot, western blot, and indirect immunofluorescence analyses. The protective efficacy against Newcastle disease and avian influenza of subtype H6 was evaluated in 3-wk-old chickens and turkeys. A single vaccination protected specific-pathogen-free (SPF) chickens against a subsequent lethal NDV infection and prevented shedding of AIV after homologous H6 LPAIV infection. Furthermore, vaccinated and AIV-infected animals could be differentiated by detection of AIV nucleoprotein-specific antibodies. Three-week-old commercial turkeys, exhibiting NDV-specific maternal antibodies, were partially protected against a lethal NDV challenge infection. The mortality rate of NDVH6-immunized turkeys was reduced to 40% compared to 90% in unvaccinated birds. After H6 LPAIV infection, shedding in NDVH6-immunized turkeys was only marginally reduced compared to NDV-immunized control birds. We previously described HA-expressing NDV recombinants as potent bivalent vaccines against Newcastle disease and highly pathogenic avian influenza of subtype H5 or H7. The results presented here are in contrast to the high protective efficacy in SPF chickens, as a single vaccination with NDVH6 was insufficient in turkeys in the presence of maternal antibodies against NDV. Therefore, the vector virus has to be improved to overcome these limitations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21793434     DOI: 10.1637/9539-092710-Reg.1

Source DB:  PubMed          Journal:  Avian Dis        ISSN: 0005-2086            Impact factor:   1.577


  9 in total

Review 1.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

Review 2.  Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use.

Authors:  Julia P C Fulber; Amine A Kamen
Journal:  Viruses       Date:  2022-05-06       Impact factor: 5.818

3.  Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines.

Authors:  John N Mason; Husni Elbahesh; Charles J Russell
Journal:  J Virol       Date:  2013-03-20       Impact factor: 5.103

4.  Newcastle disease virus-based H5 influenza vaccine protects chickens from lethal challenge with a highly pathogenic H5N2 avian influenza virus.

Authors:  Jingjiao Ma; Jinhwa Lee; Haixia Liu; Ignacio Mena; A Sally Davis; Sun Young Sunwoo; Yuekun Lang; Michael Duff; Igor Morozov; Yuhao Li; Jianmei Yang; Adolfo García-Sastre; Juergen A Richt; Wenjun Ma
Journal:  NPJ Vaccines       Date:  2017-12-04       Impact factor: 7.344

Review 5.  Exploring the Prospects of Engineered Newcastle Disease Virus in Modern Vaccinology.

Authors:  Muhammad Bashir Bello; Khatijah Yusoff; Aini Ideris; Mohd Hair-Bejo; Abdurrahman Hassan Jibril; Ben P H Peeters; Abdul Rahman Omar
Journal:  Viruses       Date:  2020-04-16       Impact factor: 5.048

Review 6.  Newcastle disease vaccines-A solved problem or a continuous challenge?

Authors:  Kiril M Dimitrov; Claudio L Afonso; Qingzhong Yu; Patti J Miller
Journal:  Vet Microbiol       Date:  2016-12-16       Impact factor: 3.293

7.  Generation and Evaluation of Recombinant Thermostable Newcastle Disease Virus Expressing the HA of H9N2 Avian Influenza Virus.

Authors:  Xiaorong Zhang; Zongyi Bo; Chenchen Meng; Yin Chen; Chengcheng Zhang; Yongzhong Cao; Yantao Wu
Journal:  Viruses       Date:  2021-08-13       Impact factor: 5.048

Review 8.  Avian Orthoavulavirus Type-1 as Vaccine Vector against Respiratory Viral Pathogens in Animal and Human.

Authors:  Julianne Vilela; Mohammed A Rohaim; Muhammad Munir
Journal:  Vaccines (Basel)       Date:  2022-02-08

Review 9.  Viral vector-based influenza vaccines.

Authors:  Rory D de Vries; Guus F Rimmelzwaan
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.